Sentien Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 11

Sentien General Information

Description

Operator of a clinical-stage biotechnology company intended to treat patients suffering from a dysregulated immune system. The company helps to restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases and the blood conditioning approach has been proven to significantly enhance exposure, enabling patients to receive treatment for acute kidney injury and restoring balance to the immune system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Corporate Office
  • 99 Hayden Avenue
  • Building E, Suite 140
  • Lexington, MA 02421
  • United States
+1 (781) 000-0000

Sentien Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sentien Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Secondary Transaction - Private 15-Mar-2023 000.00 Completed Clinical Trials - Phase 2
9. Grant 20-Sep-2021 00000 000.00 Completed Clinical Trials - Phase 1
8. Accelerator/Incubator 22-Jun-2020 000.00 Completed Clinical Trials - Phase 1
7. Debt - PPP 29-Apr-2020 00000 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series A) 28-Sep-2018 0000 000.00 0000 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2016 00.00 00.000 Completed Clinical Trials - Phase 1
4. Seed Round 12-Aug-2015 00.000 00.000 00.00 Completed Pre-Clinical Trials
3. Grant 26-Aug-2014 00.000 Completed Pre-Clinical Trials
2. Grant 01-Apr-2012 $1.37M Completed Startup
1. Grant 01-Nov-2010 $715K Completed Startup
To view Sentien’s complete valuation and funding history, request access »

Sentien Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 564,562 $0.001000 8% $3.33 $3.33 1x $3.33 11.39%
To view Sentien’s complete cap table history, request access »

Sentien Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to treat patients suffering from a dysregulated immune syste
Biotechnology
Lexington, MA
10 As of 2024
000.00
00000000000 000.00

000000

oluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occae
0000000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000

000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000000000000
Mechelen, Belgium
0000 As of 0000
00.000
00.00 0000-00-00
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sentien Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Galapagos (Biotechnology) Formerly VC-backed Mechelen, Belgium 0000 00.000 000000000 00.000
Cytokinetics Formerly VC-backed South San Francisco, CA 000 00000 0&0
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
Neurogene Formerly VC-backed New York, NY 00 00000 000000000 00000
You’re viewing 5 of 42 competitors. Get the full list »

Sentien Executive Team (7)

Name Title Board Seat Contact Info
Brian Miller Co-Founder, Chief Executive Officer, President, & Board Member
Biju Parekkadan Ph.D Scientific Co-Founder, Board Member & Scientific Advisory Board Member
Richard Ganz Executive Chairman & Board Member
Allen Nissenson MD Chief Medical Officer
You’re viewing 4 of 7 executive team members. Get the full list »

Sentien Board Members (7)

Name Representing Role Since
Biju Parekkadan Ph.D Sentien Scientific Co-Founder, Board Member & Scientific Advisory Board Member 000 0000
Richard Ganz Sentien Executive Chairman & Board Member 000 0000
You’re viewing 2 of 7 board members. Get the full list »

Sentien Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sentien Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
TEDCO Venture Capital Minority 000 0000 000000 0
MedTech Innovator Accelerator/Incubator 000 0000 000000 0
Chiesi Ventures Corporate Venture Capital Minority 000 0000 000000 0
Mass Medical Angels Venture Capital Minority 000 0000 000000 0
Mission BioCapital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »